Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity

Company Overview - Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is a San Diego-based drug developer that completed its initial public offering (IPO) in 1996, raising $36.75 million [2]. Investment Insights - The investment group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts to watch for, buy and sell ratings, product sales forecasts, and integrated financial statements [2]. Analyst Background - The article is authored by a biotech consultant with over 5 years of experience covering biotech, healthcare, and pharma, having prepared detailed reports on over 1,000 companies [2].